Historical Valuation
AstraZeneca PLC (AZN) is now in the Fair zone, suggesting that its current forward PE ratio of 18.07 is considered Fairly compared with the five-year average of 17.09. The fair price of AstraZeneca PLC (AZN) is between 74.56 to 106.16 according to relative valuation methord.
Relative Value
Fair Zone
74.56-106.16
Current Price：94.39
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
AstraZeneca PLC (AZN) has a current Price-to-Book (P/B) ratio of 6.18. Compared to its 3-year average P/B ratio of 5.43 , the current P/B ratio is approximately 13.78% higher. Relative to its 5-year average P/B ratio of 5.93, the current P/B ratio is about 4.17% higher. AstraZeneca PLC (AZN) has a Forward Free Cash Flow (FCF) yield of approximately 4.46%. Compared to its 3-year average FCF yield of 4.32%, the current FCF yield is approximately 3.25% lower. Relative to its 5-year average FCF yield of 3.89% , the current FCF yield is about 14.68% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for AZN competitors is 4.87, providing a benchmark for relative valuation. AstraZeneca PLC Corp (AZN.O) exhibits a P/S ratio of 4.62, which is -5.21% above the industry average. Given its robust revenue growth of 11.99%, this premium appears unsustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of AZN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AZN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AZN currently overvalued or undervalued?
AstraZeneca PLC (AZN) is now in the Fair zone, suggesting that its current forward PE ratio of 18.07 is considered Fairly compared with the five-year average of 17.09. The fair price of AstraZeneca PLC (AZN) is between 74.56 to 106.16 according to relative valuation methord.
What is AstraZeneca PLC (AZN) fair value?
AZN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of AstraZeneca PLC (AZN) is between 74.56 to 106.16 according to relative valuation methord.
How does AZN's valuation metrics compare to the industry average?
The average P/S ratio for AZN's competitors is 4.87, providing a benchmark for relative valuation. AstraZeneca PLC Corp (AZN) exhibits a P/S ratio of 4.62, which is -5.21% above the industry average. Given its robust revenue growth of 11.99%, this premium appears unsustainable.
What is the current P/B ratio for AstraZeneca PLC (AZN) as of Jan 17 2026?
As of Jan 17 2026, AstraZeneca PLC (AZN) has a P/B ratio of 6.18. This indicates that the market values AZN at 6.18 times its book value.
What is the current FCF Yield for AstraZeneca PLC (AZN) as of Jan 17 2026?
As of Jan 17 2026, AstraZeneca PLC (AZN) has a FCF Yield of 4.46%. This means that for every dollar of AstraZeneca PLC’s market capitalization, the company generates 4.46 cents in free cash flow.
What is the current Forward P/E ratio for AstraZeneca PLC (AZN) as of Jan 17 2026?
As of Jan 17 2026, AstraZeneca PLC (AZN) has a Forward P/E ratio of 18.07. This means the market is willing to pay $18.07 for every dollar of AstraZeneca PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for AstraZeneca PLC (AZN) as of Jan 17 2026?
As of Jan 17 2026, AstraZeneca PLC (AZN) has a Forward P/S ratio of 4.62. This means the market is valuing AZN at $4.62 for every dollar of expected revenue over the next 12 months.